TCF7 and neoplasm: In solid tumor therapy, the key to the success of engineered T cells lies in their persistence—that is, their ability to maintain a population of T cells with stem-like properties and self-renewal capacity (such as TCF-1+ TPEX) within the tumor microenvironment characterized by chronic antigen exposure and metabolic stress [79].